SCHEMBL3853309

SCHEMBL3853309

O=C(Cl)c1ccc(N2CCN(C(=O)OCC3c4ccccc4-c4ccccc43)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 2/20 0.45
KDM4E B2RXH2 1/20 0.45
F10 P00742 2/20 0.44
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.42
CHRM4 P08173 1/20 0.41
PDK2 Q15119 1/20 0.41
SSTR1 P30872 1/20 0.41
SSTR3 P32745 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4652078 0.89 MAPT (0.46) MAPTLMNAGAAKDM4EF10
SCHEMBL14599486 0.86 GAA (0.53) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL22397770 0.83 POLB (0.52) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL13327274 0.83 POLB (0.52) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL13239764 0.83 MAPT (0.47) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL7138685 0.82 MAPT (0.65) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL3219970 0.79 FABP5 (0.49) MAPTLMNAALDH1A1SMN1; SMN2TSHR
SCHEMBL4118503 0.79 MAPT (0.71) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL8222797 0.78 TSHR (0.50) LMNAGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL30555288 0.78 TSHR (0.50) LMNAGAAALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357506-B2 Method of identifying improved conjugates of biologically active compounds BURNET MICHAEL (DE) 2013-01-22 US disclosed
US-7579324-B2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof C-A-I-R BIOSCIENCES GMBH (DE) 2009-08-25 US disclosed
US-20090093014-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof Burnet, Dr. Michael (DE) 2009-04-09 US disclosed
US-20080145343-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof BURNET, MICHAEL (DE) 2008-06-19 US disclosed
EP-1483277-A4 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF MERCKLE GMBH (DE) 2007-10-03 EP disclosed
EP-1483579-A4 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF MERCKLE GMBH (DE) 2006-07-12 EP disclosed
US-20060099660-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof SYNOVO GMBH (DE) 2006-05-11 US disclosed
US-20050171342-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof MERCKLE GMBH (DE) 2005-08-04 US disclosed
EP-1483579-A2 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF Sympore GmbH (DE) 2004-12-08 EP disclosed
EP-1483277-A2 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF Sympore GmbH (DE) 2004-12-08 EP disclosed
US-20040087517-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof C-A-I-R BIOSCIENCES GMBH (DE) 2004-05-06 US disclosed
US-20040005641-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof BURNET, DR. MICHAEL (DE) 2004-01-08 US disclosed
WO-2003070173-A2 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF SYMPORE GMBH (DE) 2003-08-28 WO disclosed
WO-2003070174-A2 CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF SYMPORE GMBH (DE) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145343-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof CD47, CD14, CD4 MAPT 3182/4885LMNA 2485/4885GAA 304/4885
US-20050171342-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof SLC7A1, CD4, SLC11A2 MAPT 2888/4885LMNA 2042/4885GAA 551/4885
US-20040005641-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof CD47, CD14, CD4 MAPT 3182/4885LMNA 2485/4885GAA 304/4885
US-20040087517-A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof SLC7A1, SLC47A1, SLC47A2 MAPT 2676/4885LMNA 1557/4885GAA 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.